{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-056378","form_type":"8-K","ticker":"QNRX","cik":"0001671502","company_name":"Quoin Pharmaceuticals, Ltd.","filed_at":"2025-06-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.280237+00:00","generated_at":"2026-05-19T23:58:14.238014+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Quoin Pharma awards CEO $331k and COO $265k in 2024 cash bonuses","bullets":["Compensation Committee approved 2024 annual cash bonus of $331,238 for CEO Dr. Michael Myers.","COO Denise Carter received 2024 annual cash bonus of $264,640.","Bonuses are consistent with CEO and COO compensation programs approved at Dec 5, 2024 shareholder meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-056378","json":"https://secwatch.observer/filing/0001104659-25-056378.json","markdown":"https://secwatch.observer/filing/0001104659-25-056378.md","text":"https://secwatch.observer/filing/0001104659-25-056378.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671502/000110465925056378/0001104659-25-056378-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671502/000110465925056378/tm2517172d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T23:58:14.238014+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}